Ok_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":600319996,"tweetId":"600319996","gmtCreate":1638066059837,"gmtModify":1638066059980,"author":{"id":3579307827566708,"idStr":"3579307827566708","authorId":3579307827566708,"authorIdStr":"3579307827566708","name":"Kimoqi","avatar":"https://static.tigerbbs.com/4a75a25c05f3caeb1708eff0d5b7effc","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":32,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":5,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/600319996","repostId":1153242523,"repostType":4,"repost":{"id":"1153242523","kind":"news","pubTimestamp":1638063498,"share":"https://www.laohu8.com/m/news/1153242523?lang=&edition=full","pubTime":"2021-11-28 09:38","market":"us","language":"en","title":"US IPO Week Ahead: December kicks off with a 1 IPO week","url":"https://stock-news.laohu8.com/highlight/detail?id=1153242523","media":"Renaissance Capital","summary":"The US IPO market is taking a breather after the holiday week, with just one IPO scheduled to raise ","content":"<p>The US IPO market is taking a breather after the holiday week, with just one IPO scheduled to raise $30 million in the first week of December.</p>\n<p>While the calendar is quiet at the moment, several IPOs are eligible to launch on Monday, including Indian IT services provider&nbsp;<b>Coforge</b>&nbsp;(CFRG.RC), cloud infrastructure platform&nbsp;<b>HashiCorp</b>&nbsp;(HCP), luxury fashion e-tailer&nbsp;<b>Rue Gilt Group</b>&nbsp;(RGG), rugged apparel brand&nbsp;<b>5.11 ABR</b>(VXI), and Florida-based insurer&nbsp;<b>TypTapInsurance Group</b>&nbsp;(TYTP).</p>\n<p>Phase 1-ready biotech&nbsp;<b>Nuvectis Pharma</b>&nbsp;(NVCT) plans to raise $30 million at a $160 million market cap. The company is initially focused the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology. Nuvectis is currently developing two preclinical candidates, with its lead candidate expected to begin a Phase 1 trial in the 4Q21.</p>\n<p><img src=\"https://static.tigerbbs.com/ebedc817c5c3858bec4f16c6152bfce8\" tg-width=\"936\" tg-height=\"163\" referrerpolicy=\"no-referrer\"></p>\n<p>Street research is expected to 12 companies in the week ahead, and lock-up periods will be expiring for up to four companies. For access to Street research and lock-up dates,sign up for a free trial of IPO Pro.</p>\n<p><b>IPO Market Snapshot</b></p>\n<p>The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 11/24/2021, the Renaissance IPO Index was down 1.1% year-to-date, while the S&amp;P 500 was up 25.2%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Moderna (MRNA). The Renaissance International IPO Index was down 22.4% year-to-date, while the ACWX was up 7.4%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Meituan-Dianping and SoftBank.</p>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: December kicks off with a 1 IPO week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: December kicks off with a 1 IPO week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-28 09:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.renaissancecapital.com/IPO-Center/News/89065/US-IPO-Week-Ahead-December-kicks-off-with-a-1-IPO-week><strong>Renaissance Capital</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The US IPO market is taking a breather after the holiday week, with just one IPO scheduled to raise $30 million in the first week of December.\nWhile the calendar is quiet at the moment, several IPOs ...</p>\n\n<a href=\"https://www.renaissancecapital.com/IPO-Center/News/89065/US-IPO-Week-Ahead-December-kicks-off-with-a-1-IPO-week\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVCT":"Nuvectis Pharma, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/89065/US-IPO-Week-Ahead-December-kicks-off-with-a-1-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153242523","content_text":"The US IPO market is taking a breather after the holiday week, with just one IPO scheduled to raise $30 million in the first week of December.\nWhile the calendar is quiet at the moment, several IPOs are eligible to launch on Monday, including Indian IT services provider Coforge (CFRG.RC), cloud infrastructure platform HashiCorp (HCP), luxury fashion e-tailer Rue Gilt Group (RGG), rugged apparel brand 5.11 ABR(VXI), and Florida-based insurer TypTapInsurance Group (TYTP).\nPhase 1-ready biotech Nuvectis Pharma (NVCT) plans to raise $30 million at a $160 million market cap. The company is initially focused the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology. Nuvectis is currently developing two preclinical candidates, with its lead candidate expected to begin a Phase 1 trial in the 4Q21.\n\nStreet research is expected to 12 companies in the week ahead, and lock-up periods will be expiring for up to four companies. For access to Street research and lock-up dates,sign up for a free trial of IPO Pro.\nIPO Market Snapshot\nThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 11/24/2021, the Renaissance IPO Index was down 1.1% year-to-date, while the S&P 500 was up 25.2%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Moderna (MRNA). The Renaissance International IPO Index was down 22.4% year-to-date, while the ACWX was up 7.4%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Meituan-Dianping and SoftBank.","news_type":1},"isVote":1,"tweetType":1,"viewCount":299,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/600319996"}